Cargando…

813. Characteristics and Outcomes of Hospitalized Patients with Newly Diagnosed Histoplasmosis

BACKGROUND: Histoplasmosis (histo), is the most common cause of hospitalization and death among the endemic mycoses in the US. Clinical presentation varies from asymptomatic to severe, disseminated illness indistinguishable from other infections, which may result in misdiagnosis. Physicians must rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalton, Liam, Miceli, Marisa H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678222/
http://dx.doi.org/10.1093/ofid/ofad500.858
_version_ 1785150311382384640
author Dalton, Liam
Miceli, Marisa H
author_facet Dalton, Liam
Miceli, Marisa H
author_sort Dalton, Liam
collection PubMed
description BACKGROUND: Histoplasmosis (histo), is the most common cause of hospitalization and death among the endemic mycoses in the US. Clinical presentation varies from asymptomatic to severe, disseminated illness indistinguishable from other infections, which may result in misdiagnosis. Physicians must remain vigilant for histo given the potentially devastating consequences of disseminated infection. We sought to determine the characteristics and outcomes of admitted patients (pt) newly diagnosed with histo at our institution. METHODS: We performed a retrospective evaluation of hospitalized adult pt newly diagnosed with histo via culture, histopathology, or antigen testing (Ag) at the University of Michigan from 1/1/2015-12/31/2022. Demographic, clinical, treatment, & outcome data were collected. We compared the characteristics and outcomes of immunocompromised (IC) pt with those of non-immunocompromised (NIC) pt. RESULTS: 62 pt were included, 51 IC (76%) & 16 NIC (24%). The IC group included pt with solid organ transplants (19), autoimmune disorders treated with immunosuppressive drugs (22), hematologic (4) or solid malignancies & AIDS (1 each). Mean age of IC was 46.13+17.4 yr vs 58.1+16.4 yr among NIC, p=0.02; 74% IC were men vs 80% NIC. Mean BMI in IC pt was 26.8+6.2 vs 24.1+5.2 among NIC, p=0.13. Disseminated histo was more common in IC pt (74.5% vs 46.7%, p=0.048). ICU admission occurred in 46.8% IC vs 40% NIC, p=0.75. All-cause 6-month (m) mortality was 24%: 25.5% IC vs 20% NIC; 3 pt died before diagnosis was made (2 IC; 1 NIC). The initial treatment for most IC pt was amphotericin B (76.6%, p< 0.01). Fifty-two pt were diagnosed using Ag testing (40 IC; 12 NIC); Ag titers above the limit of quantification occurred in 15 IC pt; 14 had disseminated disease. Histo was diagnosed year-round in our pt cohort, but the most pt presented in winter (39%; p=0.02). December was the m with the most cases (27.4%, p< 0.001). There was no statistical difference in diagnostic seasonality between hospitalized IC & NIC pt. CONCLUSION: Hospitalized IC pt diagnosed with histo were younger and more frequently had disseminated disease than NIC pt, but morbidity and mortality did not differ. Unlike other reports, at our institution, the most pt with histo were diagnosed during the winter months. DISCLOSURES: Marisa H. Miceli, MD, Astellas: Advisor/Consultant|F2G: Grant/Research Support|Scynexis: Advisor/Consultant|Scynexis: Grant/Research Support
format Online
Article
Text
id pubmed-10678222
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106782222023-11-27 813. Characteristics and Outcomes of Hospitalized Patients with Newly Diagnosed Histoplasmosis Dalton, Liam Miceli, Marisa H Open Forum Infect Dis Abstract BACKGROUND: Histoplasmosis (histo), is the most common cause of hospitalization and death among the endemic mycoses in the US. Clinical presentation varies from asymptomatic to severe, disseminated illness indistinguishable from other infections, which may result in misdiagnosis. Physicians must remain vigilant for histo given the potentially devastating consequences of disseminated infection. We sought to determine the characteristics and outcomes of admitted patients (pt) newly diagnosed with histo at our institution. METHODS: We performed a retrospective evaluation of hospitalized adult pt newly diagnosed with histo via culture, histopathology, or antigen testing (Ag) at the University of Michigan from 1/1/2015-12/31/2022. Demographic, clinical, treatment, & outcome data were collected. We compared the characteristics and outcomes of immunocompromised (IC) pt with those of non-immunocompromised (NIC) pt. RESULTS: 62 pt were included, 51 IC (76%) & 16 NIC (24%). The IC group included pt with solid organ transplants (19), autoimmune disorders treated with immunosuppressive drugs (22), hematologic (4) or solid malignancies & AIDS (1 each). Mean age of IC was 46.13+17.4 yr vs 58.1+16.4 yr among NIC, p=0.02; 74% IC were men vs 80% NIC. Mean BMI in IC pt was 26.8+6.2 vs 24.1+5.2 among NIC, p=0.13. Disseminated histo was more common in IC pt (74.5% vs 46.7%, p=0.048). ICU admission occurred in 46.8% IC vs 40% NIC, p=0.75. All-cause 6-month (m) mortality was 24%: 25.5% IC vs 20% NIC; 3 pt died before diagnosis was made (2 IC; 1 NIC). The initial treatment for most IC pt was amphotericin B (76.6%, p< 0.01). Fifty-two pt were diagnosed using Ag testing (40 IC; 12 NIC); Ag titers above the limit of quantification occurred in 15 IC pt; 14 had disseminated disease. Histo was diagnosed year-round in our pt cohort, but the most pt presented in winter (39%; p=0.02). December was the m with the most cases (27.4%, p< 0.001). There was no statistical difference in diagnostic seasonality between hospitalized IC & NIC pt. CONCLUSION: Hospitalized IC pt diagnosed with histo were younger and more frequently had disseminated disease than NIC pt, but morbidity and mortality did not differ. Unlike other reports, at our institution, the most pt with histo were diagnosed during the winter months. DISCLOSURES: Marisa H. Miceli, MD, Astellas: Advisor/Consultant|F2G: Grant/Research Support|Scynexis: Advisor/Consultant|Scynexis: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10678222/ http://dx.doi.org/10.1093/ofid/ofad500.858 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Dalton, Liam
Miceli, Marisa H
813. Characteristics and Outcomes of Hospitalized Patients with Newly Diagnosed Histoplasmosis
title 813. Characteristics and Outcomes of Hospitalized Patients with Newly Diagnosed Histoplasmosis
title_full 813. Characteristics and Outcomes of Hospitalized Patients with Newly Diagnosed Histoplasmosis
title_fullStr 813. Characteristics and Outcomes of Hospitalized Patients with Newly Diagnosed Histoplasmosis
title_full_unstemmed 813. Characteristics and Outcomes of Hospitalized Patients with Newly Diagnosed Histoplasmosis
title_short 813. Characteristics and Outcomes of Hospitalized Patients with Newly Diagnosed Histoplasmosis
title_sort 813. characteristics and outcomes of hospitalized patients with newly diagnosed histoplasmosis
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678222/
http://dx.doi.org/10.1093/ofid/ofad500.858
work_keys_str_mv AT daltonliam 813characteristicsandoutcomesofhospitalizedpatientswithnewlydiagnosedhistoplasmosis
AT micelimarisah 813characteristicsandoutcomesofhospitalizedpatientswithnewlydiagnosedhistoplasmosis